NASDAQ:CERS Cerus - CERS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cerus Co. Please log in to your account or sign up in order to add this asset to your watchlist. $3.10 0.00 (0.00%) (As of 01/26/2023 12:00 AM ET) Add Compare Share Share Today's Range$3.05▼$3.2150-Day Range$2.72▼$4.2252-Week Range$2.53▼$6.00Volume865,459 shsAverage Volume1.77 million shsMarket Capitalization$550.01 millionP/E RatioN/ADividend YieldN/APrice Target$4.88 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Cerus MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside57.3% Upside$4.88 Price TargetShort InterestBearish3.54% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.14Based on 7 Articles This WeekInsider TradingSelling Shares$48,875 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.21) to ($0.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.95 out of 5 starsMedical Sector678th out of 1,048 stocksSurgical & Medical Instruments Industry66th out of 104 stocks 3.2 Analyst's Opinion Consensus RatingCerus has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.88, Cerus has a forecasted upside of 57.3% from its current price of $3.10.Amount of Analyst CoverageCerus has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.54% of the outstanding shares of Cerus have been sold short.Short Interest Ratio / Days to CoverCerus has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Cerus has recently increased by 11.74%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCerus does not currently pay a dividend.Dividend GrowthCerus does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CERS. Previous Next 2.3 News and Social Media Coverage News SentimentCerus has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Cerus this week, compared to 2 articles on an average week.Search Interest15 people have searched for CERS on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cerus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $48,875.00 in company stock.Percentage Held by InsidersOnly 7.33% of the stock of Cerus is held by insiders.Percentage Held by Institutions82.47% of the stock of Cerus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cerus are expected to grow in the coming year, from ($0.21) to ($0.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cerus is -14.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cerus is -14.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCerus has a P/B Ratio of 6.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cerus (NASDAQ:CERS) StockCerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.Read More Receive CERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter. Email Address CERS Stock News HeadlinesJanuary 23, 2023 | americanbankingnews.comBTIG Research Lowers Cerus (NASDAQ:CERS) to NeutralJanuary 23, 2023 | americanbankingnews.comCerus (NASDAQ:CERS) Downgraded by BTIG ResearchJanuary 26, 2023 | Investing Trends (Ad)Profit From the Commercial Solar Boom?Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered. January 17, 2023 | americanbankingnews.comCerus (NASDAQ:CERS) Downgraded by StephensJanuary 9, 2023 | finance.yahoo.comCerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2022 Product Revenue and Provides Business UpdateDecember 21, 2022 | finance.yahoo.comCerus Corporation's (NASDAQ:CERS) recent 9.2% pullback adds to one-year year losses, institutional owners may take drastic measuresNovember 21, 2022 | benzinga.comCerus's Return On Capital Employed OverviewNovember 9, 2022 | finance.yahoo.comCerus Third Quarter 2022 Earnings: US$0.048 loss per share (vs US$0.072 loss in 3Q 2021)January 26, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.November 3, 2022 | finance.yahoo.comCerus Corporation Announces Third Quarter Financial ResultsNovember 2, 2022 | finance.yahoo.comCerus Corporation Announces Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized CryoprecipitateNovember 1, 2022 | finance.yahoo.comCerus Corporation Announces Health Canada Approval for INTERCEPT Blood System for Platelets with Seven-Day StorageOctober 20, 2022 | finance.yahoo.comCerus Corporation to Release Third Quarter 2022 Financial Results on November 3, 2022October 2, 2022 | fool.comCerus (NASDAQ: CERS)September 29, 2022 | seekingalpha.comCerus Stock: Technical Support Fades, Investment Case Weakens (NASDAQ:CERS) - Seeking AlphaSeptember 29, 2022 | nasdaq.comDoes Cerus (NASDAQ:CERS) Have A Healthy Balance Sheet?September 26, 2022 | benzinga.comCerus Corporation Announces Workshop and Abstracts at the 2022 AABB Annual Meeting - Cerus (NASDAQ:CERS) - BenzingaSeptember 26, 2022 | finance.yahoo.comCerus Corporation Announces Workshop and Abstracts at the 2022 AABB Annual MeetingSeptember 21, 2022 | finance.yahoo.comAfter Plunging 17.6% in 4 Weeks, Here's Why the Trend Might Reverse for Cerus (CERS)September 19, 2022 | finance.yahoo.comCerus Corporation (CERS)September 14, 2022 | finance.yahoo.comInvestors in Cerus (NASDAQ:CERS) have made a decent return of 59% over the past five years - Yahoo FinanceSeptember 14, 2022 | finance.yahoo.comInvestors in Cerus (NASDAQ:CERS) have made a decent return of 59% over the past five yearsSeptember 13, 2022 | nasdaq.comZimmer (ZBH) Surges 4.2%: Is This an Indication of Further Gains? - NasdaqSeptember 11, 2022 | reuters.comCERS.O - Cerus Corporation | Stock Price & Latest News | ReutersSeptember 10, 2022 | reuters.comCERS.OQ - Cerus Corporation | Stock Price & Latest News | ReutersSeptember 6, 2022 | streetinsider.comInstil Bio Announces Appointment of Tim Moore as Chief Operating Officer - StreetInsider.comSeptember 1, 2022 | globenewswire.comBlood Purification Devices Market Size Will Achieve USD - GlobeNewswireSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter. Email Address CERS Company Calendar Last Earnings11/03/2022Today1/26/2023Next Earnings (Estimated)2/28/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:CERS CUSIP15708510 CIK1020214 Webwww.cerus.com Phone(925) 288-6000Fax925-288-6001Employees631Year Founded1991Price Target and Rating Average Stock Price Forecast$4.88 High Stock Price Forecast$6.00 Low Stock Price Forecast$3.75 Forecasted Upside/Downside+57.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,380,000.00 Net Margins-24.24% Pretax Margin-24.09% Return on Equity-48.32% Return on Assets-17.18% Debt Debt-to-Equity Ratio0.37 Current Ratio1.73 Quick Ratio1.44 Sales & Book Value Annual Sales$130.86 million Price / Sales4.20 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book6.20Miscellaneous Outstanding Shares177,421,000Free Float164,416,000Market Cap$550.01 million OptionableOptionable Beta1.09 Social Links Key ExecutivesMr. William M. Greenman (Age 56)Pres, CEO & Director Comp: $1.25MDr. Laurence M. Corash (Age 79)Co-Founder & Chief Scientific Officer Comp: $697.77kMr. Kevin D. Green (Age 51)VP of Fin. & CFO Comp: $698.15kMr. Vivek K. Jayaraman (Age 48)Chief Operating Officer Comp: $845.3kDr. Richard J. Benjamin (Age 63)Chief Medical Officer Comp: $718.64kMs. Lori L. RollVP of Admin. & Corp. Sec.Mr. Matthew M. NotarianniSr. Director of Investor RelationsMs. Chrystal N. Menard (Age 52)Chief Legal Officer & Gen. Counsel Lainie CortenVP of Global MarketingMs. Carol M. Moore (Age 73)Sr. VP of Regulatory Affairs, Quality & Clinical More ExecutivesKey CompetitorsAnika TherapeuticsNASDAQ:ANIKOraSure TechnologiesNASDAQ:OSURUtah Medical ProductsNASDAQ:UTMDAtrionNASDAQ:ATRICardiovascular SystemsNASDAQ:CSIIView All CompetitorsInsiders & InstitutionsStephens Inc. ARSold 17,010 shares on 1/25/2023Ownership: 0.358%ARK Investment Management LLCSold 990,491 shares on 1/24/2023Ownership: 8.941%Bouvel Investment Partners LLCBought 8,440 shares on 1/19/2023Ownership: 0.127%Exchange Traded Concepts LLCSold 4,665 shares on 1/18/2023Ownership: 0.137%Assenagon Asset Management S.A.Bought 9,582 shares on 1/12/2023Ownership: 1.410%View All Insider TransactionsView All Institutional Transactions CERS Stock - Frequently Asked Questions Should I buy or sell Cerus stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CERS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERS, but not buy additional shares or sell existing shares. View CERS analyst ratings or view top-rated stocks. What is Cerus' stock price forecast for 2023? 3 brokerages have issued 1-year price targets for Cerus' stock. Their CERS share price forecasts range from $3.75 to $6.00. On average, they expect the company's share price to reach $4.88 in the next year. This suggests a possible upside of 59.3% from the stock's current price. View analysts price targets for CERS or view top-rated stocks among Wall Street analysts. How have CERS shares performed in 2023? Cerus' stock was trading at $3.65 on January 1st, 2023. Since then, CERS shares have decreased by 16.2% and is now trading at $3.06. View the best growth stocks for 2023 here. Are investors shorting Cerus? Cerus saw a increase in short interest in January. As of January 15th, there was short interest totaling 6,280,000 shares, an increase of 11.7% from the December 31st total of 5,620,000 shares. Based on an average daily trading volume, of 1,310,000 shares, the days-to-cover ratio is currently 4.8 days. View Cerus' Short Interest. When is Cerus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023. View our CERS earnings forecast. How were Cerus' earnings last quarter? Cerus Co. (NASDAQ:CERS) issued its quarterly earnings data on Thursday, November, 3rd. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). The biotechnology company earned $39.57 million during the quarter, compared to analyst estimates of $39 million. Cerus had a negative net margin of 24.24% and a negative trailing twelve-month return on equity of 48.32%. What guidance has Cerus issued on next quarter's earnings? Cerus updated its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $160.00 million-$162.00 million, compared to the consensus revenue estimate of $173.50 million. What is William M. (Obi) Greenman's approval rating as Cerus' CEO? 15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among the company's employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Cerus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA). What is Cerus' stock symbol? Cerus trades on the NASDAQ under the ticker symbol "CERS." Who are Cerus' major shareholders? Cerus' stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (8.94%), Assenagon Asset Management S.A. (1.41%), Stephens Inc. AR (0.36%), Exchange Traded Concepts LLC (0.14%) and Bouvel Investment Partners LLC (0.13%). Insiders that own company stock include Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson, Timothy L Moore, Vivek K Jayaraman, Vivek K Jayaraman and William Mariner Greenman. View institutional ownership trends. How do I buy shares of Cerus? Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cerus' stock price today? One share of CERS stock can currently be purchased for approximately $3.06. How much money does Cerus make? Cerus (NASDAQ:CERS) has a market capitalization of $542.91 million and generates $130.86 million in revenue each year. The biotechnology company earns $-54,380,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis. How many employees does Cerus have? The company employs 631 workers across the globe. How can I contact Cerus? Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The official website for the company is www.cerus.com. The biotechnology company can be reached via phone at (925) 288-6000, via email at ir@cerus.com, or via fax at 925-288-6001. This page (NASDAQ:CERS) was last updated on 1/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.